Maintenance of intestinal epithelial barrier integrity by a combination of probiotics, herbal extract, and vitamins.


Journal

Minerva pediatrics
ISSN: 2724-5780
Titre abrégé: Minerva Pediatr (Torino)
Pays: Italy
ID NLM: 101777303

Informations de publication

Date de publication:
11 May 2023
Historique:
medline: 11 5 2023
pubmed: 11 5 2023
entrez: 11 5 2023
Statut: aheadofprint

Résumé

Irritable bowel syndrome (IBS) and Inflammatory bowel disease (IBD) are pathological conditions that severely hamper the quality of life of patients. Especially in pediatric and adolescent patients, the use of Complementary and alternative medicine is an appealing approach as an adjuvant for the management of symptoms, limiting the detrimental effect of the conventional therapy. In this work, we tested the effect of Enterokind Junior (EntJ), a mix of two probiotic strains Lactobacillus reuteri DSM 25175 and Lactobacillus acidophilus DSM 24936, Matricaria Chamomilla, and vitamins, in in vitro model of intestinal inflammation. Caco-2 cells were subjected to LPS treatment or THP-1 cells stimulated with LPS treatment, as paradigms of inflammatory conditions. The effect of the probiotic formulation was evaluated by measuring Caco-2 monolayer's Transepithelial Electrical resistance (TEER) and paracellular permeability alterations, tight junction proteins expression and localization by confocal microscopy, and release of pro-inflammatory cytokines (TNF-α and IL-8) by ELISA assay. Results demonstrated that upon impairment of intestinal parameters induced by inflammatory stimuli, the combination of probiotic was able to prevent TEER decrease and paracellular permeability alterations and to maintain the tight junction expression and localization. Moreover, the release of proinflammatory cytokines induced by inflammation was reduced by EntJ treatment. This work, in line with previous observations, supports a protective role of Lactobacillus reuteri DSM 25175, Lactobacillus acidophilus DSM 24936 and the other components in the maintenance of a healthy gut, holding up the use of this combination as an adjuvant for irritable bowel syndrome-related symptoms management.

Sections du résumé

BACKGROUND BACKGROUND
Irritable bowel syndrome (IBS) and Inflammatory bowel disease (IBD) are pathological conditions that severely hamper the quality of life of patients. Especially in pediatric and adolescent patients, the use of Complementary and alternative medicine is an appealing approach as an adjuvant for the management of symptoms, limiting the detrimental effect of the conventional therapy. In this work, we tested the effect of Enterokind Junior (EntJ), a mix of two probiotic strains Lactobacillus reuteri DSM 25175 and Lactobacillus acidophilus DSM 24936, Matricaria Chamomilla, and vitamins, in in vitro model of intestinal inflammation. Caco-2 cells were subjected to LPS treatment or THP-1 cells stimulated with LPS treatment, as paradigms of inflammatory conditions.
METHODS METHODS
The effect of the probiotic formulation was evaluated by measuring Caco-2 monolayer's Transepithelial Electrical resistance (TEER) and paracellular permeability alterations, tight junction proteins expression and localization by confocal microscopy, and release of pro-inflammatory cytokines (TNF-α and IL-8) by ELISA assay.
RESULTS RESULTS
Results demonstrated that upon impairment of intestinal parameters induced by inflammatory stimuli, the combination of probiotic was able to prevent TEER decrease and paracellular permeability alterations and to maintain the tight junction expression and localization. Moreover, the release of proinflammatory cytokines induced by inflammation was reduced by EntJ treatment.
CONCLUSIONS CONCLUSIONS
This work, in line with previous observations, supports a protective role of Lactobacillus reuteri DSM 25175, Lactobacillus acidophilus DSM 24936 and the other components in the maintenance of a healthy gut, holding up the use of this combination as an adjuvant for irritable bowel syndrome-related symptoms management.

Identifiants

pubmed: 37166776
pii: S2724-5276.23.07128-8
doi: 10.23736/S2724-5276.23.07128-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Veronica Cocetta (V)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Isabella Giacomini (I)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Mattia Tinazzi (M)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Massimiliano Berretta (M)

Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Vincenzo Quagliariello (V)

Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale of Napoli, Napoli, Italy.

Nicola Maurea (N)

Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale of Napoli, Napoli, Italy.

Eugenio Ragazzi (E)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Ilaria Carnevali (I)

Scientific Department Schwabe Pharma Italia, Egna, Bolzano, Italy.

Monica Montopoli (M)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.
VIMM - Veneto Institute of Molecular Medicine, Padova, Italy.

Classifications MeSH